Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PUBM +28.1%, TMDX +24.8%, HIMS +21.9%, EVER +17.9%, ARQT +14.6%, ZM +13.2%, HLIO +11.2%, TREX +7.6%, TARS +5.5%, TILE +4.8%, DORM +4.7%, BEAM +4.7%, BNS +3.6%, STRL +3.4%, SLCA +2.8%, AEP +2.7% (appoints interim CEO), CRI +1.9%, NUVL +1.6%, SNN +1.5%, IIPR +1.4%, AES +1.3%, DRQ +1.2%, SWTX +1.2%, ADUS +0.8%
Other news:
- JANX +84.9% (announces encouraging data from trials)
- CDXS +6.6% (licensing agreement with Roche)
- AMH +4% (replacing DOC in S&P MidCap 400)
- SCLX +3.9% (enters into term sheet with Virpax Pharmaceuticals)
- BGNE +3% ( FDA has accepted a Biologics License Application for TEVIMBRA in combination with fluoropyrimidine- and platinum-containing chemotherapy)
- PRTC +2.9% (PureTech Founded Entity Akili (AKLI) Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan)
- AL +2.4% (long-term lease agreements for Boeing aircraft)
- CDE +2% (advancing Silvertip exploration)
- RCM +1.7% (Coliseum capital issues open letter to board)
- NWBI +1.4% (appoints new CFO)
- TCBK +1.4% (increases dividend)
- LAAC +1% (appoints new CEO)